CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
+$0.10 today
- Market cap
- $257.29M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
Volume 0.19M
Average 0.10M
CAMP Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
CAMP4 Therapeutics CorporationNASDAQ: CAMP
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin widens to -1416.6%
Net margin was -1416.6% in Q1 FY2026, up 32.5 pp from a year earlier. On a trailing-twelve-month basis it was -2193.7%, up 1234.9 pp year over year.
Context
- Net margin widened in 2 of the last 2 fiscal years.
- FY2025 was the highest level in the 3 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 7 analysts of -523.2% for the fiscal year ending Dec 2026, up from -2298.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -1416.6%+10159.2 pp QoQ
- Last fiscal yearDec 2025
- -2298.5%+5644.9 pp YoY
- LTMMar 2026
- -2193.7%+1234.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +32.5 pp | -189.5 pp | -222.0 pp |
| 1 year | +5644.9 pp | +1775.3 pp | -3869.5 pp |
| 3 years | — | +1504.5 pp | — |
| 5 years | +2170.2 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -2298.5%
- Year-over-year change
- +5644.9pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -2298.5% | +5644.9pp |
| FY2024 | 2024-12-31 | -7943.4% | +6139.7pp |
| FY2023 | 2023-11-30 | -14083.1% | — |
| FY2022 | 2023-02-28 | — | — |
| FY2021 | 2022-02-28 | -10.5% | — |
Net Margin vs competitors
How CAMP compares with its peers on the latest reported figures
- CAMP's LTM Mar 2026 net margin of -2193.7% is the 3rd highest of the 4 companies compared; the peer median is -66.4%.
- Its year-over-year change of +1234.9 pp is the highest of 3, against a peer median of +165.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 14.5% | +137.1 pp | +100715.3 pp | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | -66.4% | +193.3 pp | -37.0 pp |
| LTM Mar 2026 | -2193.7% | +1234.9 pp | — | |
| LTM Mar 2026 | -36857.4% | — | -38572.9 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding CAMP) | -66.4% | +165.2 pp | -37.0 pp | |
Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Feb 2022 | FY2022 Feb 2023 | FY2023 Nov 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 295.84M | 0 | 350K | 652K | 3.5M |
| Cost of Revenue | 173.95M | 0 | 0 | 0 | 1.64M |
| Gross Profit | 121.89M | (947K) | 350K | 652K | 1.86M |
| Gross Margin | 41.2% | — | 100.0% | 100.0% | 53.1% |
| Research & Development | 28.44M | 34.77M | 40.62M | 38.82M | 38.2M |
| Selling, General & Admin | 100.9M | 10.23M | 11.61M | 14.92M | 17.36M |
| Operating Expenses | 134.76M | 45M | 52.23M | 53.74M | 53.92M |
| Depreciation & Amortization | 22.8M | 878K | 1.68M | 1.7M | 1.64M |
| EBITDA | 7.49M | (44.12M) | (50.2M) | (51.39M) | (50.42M) |
| EBITDA Margin | 2.5% | — | -14343.1% | -7882.2% | -1441.5% |
| Operating Income | (15.31M) | (45M) | (51.88M) | (53.09M) | (52.06M) |
| Operating Margin | -5.2% | — | -14822.6% | -8142.3% | -1488.3% |
| Interest Income | 0 | 0 | 2.81M | 1.33M | 2.17M |
| Interest Expense | 15.32M | 6.26M | 0 | 0 | 0 |
| Other Income / Expenses | (14.75M) | 809K | 2.59M | 1.3M | (28.34M) |
| Income Before Tax | (30.06M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Pre-Tax Margin | -10.2% | — | -14083.1% | -7943.4% | -2298.5% |
| Income Tax Expense | 1.09M | 0 | 0 | 0 | 0 |
| Net Income | (31.15M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Net Margin | -10.5% | — | -14083.1% | -7943.4% | -2298.5% |
| EPS (Basic) | (0.88) | (0.90) | (4.07) | (2.66) | (2.65) |
| EPS (Diluted) | (0.88) | (0.90) | (4.07) | (2.66) | (2.65) |
| Weighted Avg Shares | 35.25M | 36.1M | 12.12M | 19.51M | 30.38M |
| Weighted Avg Shares (Diluted) | 35.25M | 36.13M | 12.12M | 19.51M | 30.38M |
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
Intrinsic Alpha fair value
Locked
Current Price
$4.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.